Uppsala, Sweden

Ruta Muceniece


Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 2006-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Ruta Muceniece: Pioneering Melanocortin 1 Receptor Compounds

Introduction: Ruta Muceniece, an accomplished inventor based in Uppsala, Sweden, has made significant contributions to the field of pharmaceuticals with her innovative work on selective compounds targeting the melanocortin 1 receptor. With a total of two patents, her research aims to address a wide range of inflammatory conditions through advanced therapeutic methods.

Latest Patents: Muceniece's most recent patents revolve around melanocortin 1 receptor selective compounds. The first invention relates to methods of treatment that involve the administration of a compound of the general formula (1) to patients or healthy individuals. The details of the compound emphasize its high selectivity and affinity for MC1-receptors, while exhibiting low affinity for other subtypes, thereby enhancing its effectiveness in treating inflammatory conditions. Furthermore, the patent includes a DNA molecule and a corresponding vector encoding the compound, as well as a fusion protein and a pharmaceutical composition comprising the compound.

Career Highlights: Ruta Muceniece is currently associated with Action Pharma A/S, where her research and innovations play a crucial role in developing novel therapeutic solutions. Her relentless pursuit of innovation stands out as a hallmark of her career, establishing her as a figure of influence in the pharmaceutical industry.

Collaborations: Throughout her career, Muceniece has collaborated with several notable coworkers, including Michael Szardenings and Ilze Mutule. Their collective expertise fosters a dynamic environment for research and development, enhancing the potential for groundbreaking discoveries in therapeutics.

Conclusion: Ruta Muceniece continues to advance the field of medicine through her innovative work on melanocortin 1 receptor selective compounds. Her patents not only signify her contributions to science and technology but also hold promise for future therapies addressing inflammation and related health concerns. As she progresses in her career, her inventions are likely to have a lasting impact on the pharmaceutical landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…